Table 1 AGREE II instrument-domains and items
Domain | Item | |
|---|---|---|
Number | Content | |
1. Scope and purpose | 1 | The overall objective(s) of the guideline is (are) specifically described |
2 | The clinical question(s) covered by the guideline is (are) specifically described | |
3 | The population to whom the guideline is mean to apply is specifically described | |
2. Stakeholder involvement | 4 | The guideline development group includes individuals from all relevant professional groups |
5 | The views and preferences of the target population have been sought | |
6 | The target users of the guideline are clearly defined | |
3. Rigour of development | 7 | Systematic methods were used to search for evidence |
8 | The criteria for selecting the evidence are clearly described | |
9 | The strengths and limitations of the body of evidence are clearly described | |
10 | The methods for formulating the recommendations are clearly described | |
11 | The health benefits, side effects, and risks have been considered in formulating the recommendations | |
12 | There is an explicit link between the recommendations and the supporting evidence | |
13 | The guideline has been externally reviewed by experts prior to its publication | |
14 | A procedure for updating the guideline is provided | |
4. Clarity of presentation | 15 | The recommendations are specific and unambiguous |
16 | The different options for management of the condition or health issue are clearly presented | |
17 | Key recommendations are easily identifiable | |
5. Applicability | 18 | The guideline describes facilitators and barriers to its application |
19 | The guideline provides advice and/or tools on how the recommendations can be put into practice | |
20 | The potential resource implications of applying the recommendations have been considered | |
21 | The guideline presents monitoring and/or auditing criteria | |
6. Editorial independence | 22 | The views of the funding body have not influenced the content of the guideline |
23 | Competing interests of guideline development group members have been recorded and addressed | |
Overall assessment | 1 | Overall quality of this guideline |
2 | Would you recommend this guideline for use? | |